CD4 and acute lymphoblastic leukemia: Murine models of AML and T-ALL reveal that VIPhyb, a peptide antagonist of VIP signaling, enhances IFN-γ secretion and suppresses PD-1 expression in CD4+ and CD8+ T cells (91).